Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Goodwin says it advises Dualitas on Roche antibody agreement with $36.5 million upfront
Goodwin announced that its life sciences team had advised Dualitas Therapeutics on a research collaboration and licensing agreement with Roche. The firm said Dualitas would receive $36.5 million upfront, with potential additional payments bringing the deal value to $1 billion, plus royalties, for work on antibodies targeting immunology and inflammation diseases.
Key points
- Goodwin said Dualitas would screen more than 300,000 bispecific antibody combinations.Goodwin Procter
- The firm said Roche would handle subsequent preclinical development, regulatory, manufacturing and commercial activities.Goodwin Procter
- The announcement described additional payments tied to research, development and commercial milestones.Goodwin Procter
- Goodwin named Erini Svokos and Chris Zhong as team leaders.Goodwin Procter